BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Crossover Post-herpetic Neuralgia (PHN)
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT01305538
- Locations
- 🇺🇸
Radiant Research, Inc., Akron, Ohio, United States
🇺🇸Medex Healthcare Research, Inc, St. Louis, Missouri, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: PlaceboDrug: Anti-IP-10 Antibody
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 305
- Registration Number
- NCT01294410
- Locations
- 🇺🇸
Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr, Chevy Chase, Maryland, United States
🇺🇸Shafran Gasteroenterology Center, Winter Park, Florida, United States
🇺🇸Minnesota Gastroenterology, Pa, Plymouth, Minnesota, United States
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 94
- Registration Number
- NCT01292655
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇨🇦Local Institution, Toronto, Ontario, Canada
Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 67
- Registration Number
- NCT01290575
- Locations
- 🇺🇸
Clinical Pharmacology Of Miami Inc., Miami, Florida, United States
🇺🇸Osborne Research Center, Little Rock, Arkansas, United States
🇺🇸Mra Clinical Research, Miami, Florida, United States
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
- Conditions
- Lung Cancer - Non Small Cell Squamous
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1289
- Registration Number
- NCT01285609
- Locations
- 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸St. Francis Hospital & Health Centers, Indianapolis, Indiana, United States
🇺🇸Durham Va Medical Center (111g), Durham, North Carolina, United States
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 196
- Registration Number
- NCT01257204
- Locations
- 🇺🇸
California Liver Institute, Los Angeles, California, United States
🇮🇹Local Institution, Viale Del Policlinico, 155, Italy
🇺🇸Options Health Research, Llc, Tulsa, Oklahoma, United States
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
- Conditions
- HCV (Genotype 1)
- Interventions
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT01250366
Safety Study of Abatacept to Treat Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6367
- Registration Number
- NCT01247766
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT01245556
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Jedd D. Wolchok, Md,Phd, New York, New York, United States
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
- Conditions
- Chronic Myeloid Leukemia
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1494
- Registration Number
- NCT01244750
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Peachtree Hematology-Oncology, Atlanta, Georgia, United States
🇺🇸Emory University, Atlanta, Georgia, United States